Patel Sanj K 4

What Happened Sanj K. Patel, Chairman & CEO of Kiniksa Pharmaceuticals (KNSA), exercised options to acquire 48,565 shares at $30.93 per share (cost $1,502,115) and sold 48,565 shares in an open-market transaction at a weighted average price of $54.02 per share (proceeds $2,623,481) on May 1, 2026. The filing also reports a related derivative conversion line showing 48,565 shares at $0.00 value. The sale was executed under a 10b5-1 trading plan established October 31, 2025.

Key Details

• Transaction date: May 1, 2026 (filed same day).
• Option exercise: 48,565 shares at $30.93; total cost reported $1,502,115. (Code M)
• Open-market sale: 48,565 shares at weighted avg $54.02; total proceeds $2,623,481. (Code S)
• Reported additional derivative line: 48,565 shares at $0.00 value (reported as disposed).
• Sale execution: multiple trades at prices between $54.00 and $54.155; weighted average shown per footnote.
• Option status: fully vested and exercisable (footnote).
• Plan/authorization: sale effected pursuant to a 10b5-1 plan executed Oct 31, 2025.
• Shares owned after transaction: Not specified in the provided summary of this Form 4.
• Filing timeliness: Reported on the same date as the transactions; no late filing indicated.

Context Because the insider exercised options and sold the same number of shares the same day, this looks like a cashless/monetization of vested options rather than a separate open-market purchase. The sale was pre-planned under a 10b5-1 plan, which is commonly used to schedule insider sales in advance. This is factual reporting of transactions; it does not convey the insider’s motivations.